Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 125,606

Document Document Title
WO/2017/056092A1
A method of promoting nerve growth or regeneration in a subject in need thereof, wherein the subject is not afflicted with a substantial connective tissue damage, is provided. The method comprises administering to the subject a therapeut...  
WO/2017/054786A1
The present invention relates to an improved production method of 1-(4-fluorobenzyl)-3-(4--isobutoxybenzyl)-1-(1--methylpiperi din-4-yl)urea (Pimavanserin), an inverse agonist of the serotonin 5-HT2A receptor of formula (I). Crude pimava...  
WO/2017/055530A1
(Formula I) Compounds of formula (I) usefull for the treatment of cancer, neurodegenerative disorders and metabolic disorders.  
WO/2017/051423A1
The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), ...  
WO/2017/053613A1
Disclosed herein are methods of treating and preventing neuronal cell loss in a subject using ornithine in combination with phenylacetate or phenylbutyrate. In some embodiments, the subject has received or will receive a surgical procedu...  
WO/2017/052455A1
A composition comprising one or more effective fragments of an amylase, for use as a medicament or a dietary supplement, in particular for the treatment of hyperglycemic conditions, conditions involving hyperinsulinemia and conditions in...  
WO/2017/050803A1
The present invention relates to an agent which inhibits Kallikrein-8 for use in the treatment or prevention of Alzheimer's disease and / or its precursor stages, as well as to methods, kits and uses relating thereto, including diagnosti...  
WO/2017/051046A1
The invention relates to the use of a group of compounds with a phenothiazine nucleus of general formula (I) for the treatment of diseases of the central nervous system which present synapse abnormalities, such as autism or fragile X syn...  
WO/2017/050259A1
Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.  
WO/2017/049411A1
Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as method...  
WO/2017/051294A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defin...  
WO/2017/050791A8
The invention provides novel compounds having the general formula (I) wherein R1, R2,Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/053842A1
The invention provides methods for the treatment of seizures and epilepsy using FGF21 receptor activators.  
WO/2017/050791A1
The invention provides novel compounds having the general formula (I) wherein R1, R2,Y, W, m, n, p and q are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/053613A8
Disclosed herein are methods of treating and preventing neuronal cell loss in a subject using ornithine in combination with phenylacetate or phenylbutyrate. In some embodiments, the subject has received or will receive a surgical procedu...  
WO/2017/051585A1
[Problem] To provide an inhaling fragrance that can be taken in other than through oral administration. [Solution] The inhaling fragrance includes leaf alcohol and linalool, includes ethanol as a primary solvent, and is liquid at normal ...  
WO/2017/050171A1
Provided are crystal forms I, II, III and IV of a pyrroloquinoline quinone sodium salt and a preparation method thereof. Also provided are a pharmaceutical composition, a cosmetic composition, a functional food or a nutritional agent con...  
WO/2017/051303A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R1, R2, R3, R4 and X are...  
WO/2017/050807A1
The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl- bound N-amide moiety derived from an α-amino acid of formula I where the variables are as defined in the claims and the description. The invention furthe...  
WO/2017/051276A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined...  
WO/2017/051188A1
Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), is described, as well as compositions and combined preparations for use in the metho...  
WO/2017/053346A1
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously a...  
WO/2017/053773A1
The invention described herein relates to novel personalized methods for treating, reducing or reversing cognitive decline utilizing a number of cognitive biological functions (factors), including metabolic parameters.  
WO/2017/050978A1
The present invention relates to 2,3,4,5-tetrahydropyridin-6-amine compound inhibitors of beta-secretase having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The invention is also directed t...  
WO/2017/049470A1
The present application discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.  
WO/2017/052394A1
Novel imidazo[4,5-c]pyridine and imidazo[4,5-b]pyridine derivatives of formula (I) as antagonists of 5-HT6 receptors, particularly for use in the prevention or treatment of schizophrenia, anxiety, depression, maniac depression, epilepsy,...  
WO/2017/049069A1
The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.  
WO/2017/049001A1
A method of treating dry eye disease is provided. The method includes administering to a patient in need thereof an effective amount of a pharmaceutical composition that includes an isolated clusterin or an isolated protein substantially...  
WO/2017/046172A1
The invention relates to carbohydrate ligands and moieties, respectively, mimicking glycoepitopes comprised by glycosphingolipids of the nervous system, particularly glycoepitopes comprised by glycosphingolipids of the cerebroside, the g...  
WO/2017/048778A1
Disclosed here is a method of transporting a therapeutic or diagnostic agent across a blood-brain barrier or a blood-cochlear barrier or a blood-cerebrospinal fluid barrier of a subject, comprising administering to a subject an amount of...  
WO/2017/048159A1
The invention relates to novel N,N-substituted 3,7-diazabicyclo[3.3.1]nonanes which exhibit the characteristics of positive modulators of AMPA-receptor activity and which may be used in the prevention and treatment of diseases of the ner...  
WO/2017/047769A1
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selec...  
WO/2017/047777A1
Provided is a serotonin deficiency amelioration agent for after stress-load release, that improves serotonin deficiencies after a stress load has been released. The serotonin deficiency amelioration agent for after stress-load release ha...  
WO/2017/049252A1
The present invention generally provides vectors, compositions, and methods of using the same for treating neurological disorders, including managing pain. The compositions and methods include the use of G protein-coupled receptors and l...  
WO/2017/046117A1
Compounds of formula (I) (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modu...  
WO/2017/048808A1
The present disclosure provides variant light-responsive polypeptides, and nucleic acids comprising nucleotide sequences encoding the light-responsive polypeptides. The present disclosure provides methods, devices, and systems for contro...  
WO/2017/046794A1
Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said proces...  
WO/2017/046737A1
The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. T...  
WO/2017/049192A1
The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1- inactivation-associated disorder (e.g., fragile X syndrome).  
WO/2017/047776A1
Provided is a blood tryptophan concentration elevation inhibitor. The blood tryptophan concentration elevation inhibitor has, as an effective component thereof, lactic acid bacterium of the genus Lactobacillus, a processed product thereo...  
WO/2017/046675A1
The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined ...  
WO/2017/046739A1
The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds o...  
WO/2017/046738A1
The invention is directed to substituted triazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, X, Y, Y1, and Z are as defined herein. The compounds of the...  
WO/2017/045599A1
Provided are a cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, and the preparation and use thereof. The cyclohexane derivative has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower a...  
WO/2017/045053A1
The present invention describes an oral pharmaceutical composition containing cannabinoid(s), an oily liquid solvent and a co-solvent, and a method for preparing and using same for the treatment of neurological disorders, especially refr...  
WO/2017/048720A1
Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.  
WO/2017/042274A1
The present invention relates in a first aspect to compounds for use in the treatment of leukodystrophy whereby these compounds are quinoline derivatives, e.g. laquinimod. In a further aspect, the present invention relates to methods for...  
WO/2017/044551A1
Provided herein are methods for increasing PPARalpha activity and methods for treating PPARalpha related diseases (e.g., mitochondrial diseases).  
WO/2017/044567A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: (I). The compounds induce FOXO1 transcription factor translocation to the nucleus by modulatin...  
WO/2017/044693A1
A combination of a muscarinic cholinergic receptor agonist with a non-anticholinergic antiemetic agent, and the optional addition of an acetyl choline esterase inhibitor, for the treatment of hypocholinergic disorder of the central nervo...  

Matches 501 - 550 out of 125,606